ILC2 Regulatory Context Source Review Notes

Scope

This audit records a focused source-review pass for 10 previously provisional sources that refine ILC2 regulation, tissue-boundary interpretation, and asthma translation framing.

Sources Reviewed

• AHR cell-intrinsic restraint of intestinal ILC2s
• ILC2 regulatory network review
• tissue-specific ILC features
• ILC subset plasticity review
• RORalpha checkpoint for thymic T-cell versus ILC2 commitment
• metabolic features of ILCs review
• RXRgamma sets intestinal ILC2 activation threshold
• ADM2 promotes tissue-protective intestinal ILC2 responses
• tuft-cell IL-17RB restrains IL-25 bioavailability
• asthma immunotherapy review

Knowledge-Layer Changes

• Expanded ILC2 functional regulation mechanisms with AHR, RXRgamma, RORalpha, ADM2, tuft-cell IL-17RB/IL-25, metabolic-review, tissue-specific, plasticity, and asthma-immunotherapy framing.
• Updated ILC2, ILC2 roles in pulmonary disease, ILC in lung, and Lung ILC Core Evidence Synthesis.
• Review-level sources were kept as orientation layers rather than primary mechanistic anchors.

Boundary Rules

• Gut ILC2 AHR, RXRgamma, ADM2, and tuft-cell IL-17RB findings should remain gut-labeled unless direct pulmonary evidence is added.
• RORalpha thymic commitment evidence should be used for lineage-boundary framing, not mature lung disease regulation.
• Asthma immunotherapy review evidence should frame endotype-aware therapy logic but should not substitute for ILC-specific primary evidence.

Status

• Date: 2026-05-04
• Mode: focused manual crystallization
• Count: 10 source pages promoted from provisional to focused mode.